ScreenerHero

NAUT Nautilus Biotechnology, Inc.

NAS · US · Healthcare · Biotechnology · nautilus.bio
1.960USD+10.73%Mkt Cap: 249.07M $P/E: —

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops N…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap249.07M USD
Enterprise Value167.88M USD
Revenue (TTM)190.00K USD
Gross Profit175.00K USD
Net Income (TTM)-59.00M USD
Revenue/Share0.0020 USD
Last Price1.960 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees127
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.39
PEG—
EV/EBITDA-2.74
EV/Revenue883.59
P/S1183.84
P/B1.72
EPS (TTM)-0.45
EPS (Forward)-0.74
52W Range
0.775034% of range4.310
52W High4.310 USD
52W Low0.7750 USD
Profitability
Gross Margin92.11%
Oper. Margin-8296.32%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.59%
ROA-30.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.70M USD
CapEx (TTM)1.28M USD
FCF Margin-15483.36%
FCF Yield-11.81%
Net Debt-56.22M USD
Net Debt/EBITDA0.92
Balance Sheet
Debt/Equity0.19
Current Ratio10.14
Quick Ratio9.73
Book Value/Sh1.03 USD
Cash/Share0.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.833 USD
Upside (mean)+95.6%
Target Range3.500 USD – 4.000 USD
3.500+95.6% to mean4.000
# Analysts3
Ownership
Shares Out.127.08M
Float67.47M
Insiders32.02%
Institutions43.03%
Short Interest
Short Ratio4.4d
Short % Float6.52%
Short % Out.3.21%
Shares Short4.08M
Short (prev mo.)3.15M
Technical
SMA 501.033 (+89.8%)
SMA 2002.072 (-5.4%)
Beta0.73
S&P 52W Chg16.45%
Avg Vol (30d)4.42M
Avg Vol (10d)9.37M
Technical Indicators
RSI (14)73.8
MACD0.2089
MACD Signal0.0999
MACD Hist.+0.1090
BB Upper2.000 USD
BB Middle1.235 USD
BB Lower0.4704 USD
BB Width123.84%
ATR (14)0.2359 USD
Vol Ratio (20d)2.19x